Sahyuddin Saleh

Sahyuddin Saleh

Auto-generated profile, based on publicly available information

Sahyuddin Saleh

Division of Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in HIV & AIDS Review
Verified
Journal Article
Closed access
IWI. Nyoman Yogi Wiraguna
I. Nyoman Yogi Wiraguna
ABAndi Fachruddin Benyamin
Andi Fachruddin Benyamin
RHRisna Halim
Risna Halim
SBSyakib Bakri
Syakib Bakri
SSSahyuddin Saleh
Sahyuddin Saleh
AZandi alfian Zainuddin
andi alfian Zainuddin
Introduction: Human immunodeficiency virus (HIV) is characterized by a progressive damage of immune system, resulting in a number of opportunistic infections and hematological abnormalities, and become more severe in late stages. Hematological abnormalities are common manifestations, with...

24 May 2021 in Journal of Coloproctology
Verified
Journal Article
Open access
PDF file
RMRahmawati Minhajat
Rahmawati Minhajat
SSSahyuddin Saleh
Sahyuddin Saleh
THTutik Harjianti
Tutik Harjianti
ABAndi Fachruddin Benyamin
Andi Fachruddin Benyamin
MPMuhammad Luthfi Parewangi
Muhammad Luthfi Parewangi
SBSyakib Bakri
Syakib Bakri
Objective The present study evaluated the profile of endoglin (CD105) and vascular endothelial growth factor (VEGF) based on staging and histopathological grading of colorectal cancer as well as their relationship with bevacizumab therapy. Methods A total of 88 cases of colorectal adenocarcinoma were included in the present study. The levels of VEGF and CD105 protein were evaluated with enzyme-linked immunosorbent assay (ELISA). Results There was a significant difference in the level of CD105 (p = 0.002) between metastases and non-metastases subjects, showing that CD105 was higher in metastases subjects (4.59 ng/ml). There was no significant difference in the level of VEGF based on the presence of metastasis (p = 0.625). There was a significant difference in the levels of CD105 (p = 0.038) and VEGF (p = 0.010) between the subjects who received chemotherapy and those who did not. The CD105 level was higher in the subjects who received chemotherapy (4.43 ng/ml); conversely, the level of VEGF was lower in subjects who received chemotherapy (543.65 pg/ml). There was a statistically significant difference in the levels of CD105 (p = 0.003) and VEGF (p = 0.002) between subjects who received bevacizumab therapy and subjects who did not. The levels of CD105 were higher in subjects who received bevacizumab therapy (5.11 ng/ml); in contrast, the level of VEGF was higher in subjects who did not receive bevacizumab therapy (645.92 pg/ml). There was a significant positive correlation between CD105 and VEGF in subjects who did not receive bevacizumab (p < 0.01). Conclusion The results of this study support a hypothesis of “escape mechanism” in the failure of anti-angiogenesis therapy (anti-VEGF).